ANI pharma strengthens leadership team by adding three new executives to accelerate future growth. While Coherus and Xbrane appoint new chief financial officers, Lupin and Beximco hire new independent directors. Sandoz is certified “Global Top Employer 2021” yet again by Top Employers Institute.

Biocon Pharma’s solid-dosage plant has received FDA inspection approval but its parent company was not so lucky, with one of its sites getting hit with five observations. Indoco, Strides, and Lupin were also in the regulatory spotlight while MedPharm has moved into a new, expanded facility and Coripharma has signed a packaging deal with Stada.

Two familiar industry figures have bolstered Amneal’s board, while Latvia’s Olanfarm has turned to a Sanofi executive for external expertise. Meanwhile, both Taro and Pfenex are recruiting CFOs.

Topica began its life with a promising novel anti-fungal called luliconazole (Lulicon) in hand. The compound was developed by Nihon Nohyaku and is already approved in Japan for tinea infections. Topica's initial focus will be on advancing ongoing clinical trials of the drug in athlete's foot, but even as it begins studies in athlete's foot, a market IMS estimates to be approximately $400 million in the US alone, the end goal is a topical treatment for onychomycosis.